In an effort to design specific therapies for MYC/BCL-2 positive DLBCL, we first integrated targeted-GEP (T-GEP), fluorescence in situ hybridization (FISH) analysis, and functional characterization of replicative and oxidative stress biomarkers in two independent DLBCL cohorts. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.